Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.32 Insider Own4.07% Shs Outstand16.03M Perf Week21.38%
Market Cap30.96M Forward P/E- EPS next Y-0.60 Insider Trans-9.44% Shs Float15.39M Perf Month-30.49%
Income-36.46M PEG- EPS next Q-0.45 Inst Own17.08% Short Float11.10% Perf Quarter73.17%
Sales0.01M P/S3095.72 EPS this Y11.76% Inst Trans- Short Ratio4.45 Perf Half Y-11.08%
Book/sh0.87 P/B2.23 EPS next Y73.33% ROA-84.02% Short Interest1.71M Perf Year-78.40%
Cash/sh0.74 P/C2.59 EPS next 5Y- ROE-158.46% 52W Range0.66 - 10.50 Perf YTD81.99%
Dividend Est.- P/FCF- EPS past 5Y19.99% ROI-246.92% 52W High-81.62% Beta-0.36
Dividend TTM- Quick Ratio2.75 Sales past 5Y133.54% Gross Margin-27220.00% 52W Low192.42% ATR (14)0.33
Dividend Ex-Date- Current Ratio2.75 EPS Y/Y TTM17.57% Oper. Margin-224360.00% RSI (14)50.73 Volatility17.80% 16.65%
Employees34 Debt/Eq0.08 Sales Y/Y TTM-99.48% Profit Margin-243040.00% Recom3.00 Target Price112.50
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q14.19% Payout- Rel Volume0.56 Prev Close1.50
Sales Surprise- EPS Surprise-14.29% Sales Q/Q-100.00% EarningsNov 14 BMO Avg Volume383.96K Price1.93
SMA20-7.67% SMA5013.11% SMA200-46.40% Trades Volume213,835 Change28.67%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Resumed Wells Fargo Overweight $3
Dec-18-23 07:57AM
Nov-14-23 07:56AM
Aug-14-23 04:05PM
Jun-29-23 07:00AM
05:00PM Loading…
May-25-23 05:00PM
May-10-23 07:00AM
May-03-23 08:30AM
Apr-26-23 12:30PM
Mar-30-23 07:00AM
Mar-29-23 05:30PM
Mar-07-23 07:00AM
Feb-28-23 04:01PM
Feb-17-23 05:47AM
Jan-09-23 08:30AM
09:01AM Loading…
Nov-29-22 09:01AM
Nov-28-22 04:01PM
Nov-14-22 07:00AM
Nov-08-22 08:30AM
Nov-07-22 08:00AM
Sep-21-22 08:30AM
Sep-07-22 08:30AM
Sep-06-22 08:00AM
Aug-24-22 03:00PM
Aug-15-22 07:00AM
Aug-08-22 08:50AM
Aug-04-22 05:00PM
Jul-06-22 09:31AM
Jun-30-22 07:07AM
Jun-27-22 08:00AM
08:30AM Loading…
Jun-01-22 08:30AM
May-26-22 05:01PM
May-16-22 07:30AM
May-12-22 11:48AM
May-10-22 08:30AM
May-09-22 08:30AM
May-02-22 04:31PM
Mar-30-22 07:30AM
Mar-22-22 01:58PM
Mar-16-22 08:30AM
Mar-08-22 04:05PM
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyle Kevin S. Sr.Chief Executive OfficerSep 01Sale0.1468,0149,542798,236Sep 05 05:34 PM